

By participating in this clinical trial, you will be advancing research that may potentially change the future of flu prevention. Without people like you, researching potential new vaccines would not be possible.

Diseases do not discriminate – and neither should clinical trials

Moderna is committed to researching safe and effective mRNA-based vaccines and therapies to bring better health and living to people of all ages, sexes and backgrounds.

Interested in Participating?

Thank you for your interest in the Glow Trial. Your participation could contribute to an investigational mRNA flu vaccine. To learn more about this clinical trial, and how to join, contact the clinical trial site listed below.

[Site Staff Name] [Telephone] [Email]

References

1. World Health Organization. Influenza (seasonal): ask the expert: influenza Q&A. Published 6 November 2018. <u>https://www.who.int/news-room/fact-sheets/detail/</u>influenza-(seasonal)

2. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. *Lancet Infect Dis.* 2016;16(8):942-951. doi:10.1016/S1473-3099(16)00129-8

3. Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG. New technologies for influenza vaccines. *Microorganisms*. 2020;8(11):1745.





moderna



Potentially Help Prevent Seasonal Flu

You have the power to advance research of an investigational vaccine that may change the future of seasonal flu with 1 injection. Learn more about participating in the Glow Trial for an investigational vaccine aimed at preventing seasonal flu infection. The investigational vaccine uses Moderna's advanced messenger RNA (mRNA) science.



About the Glow Trial

Clinical trials, and the volunteers who participate in them, are vital to creating vaccines. Vaccines aim to safely protect people against infections. The purpose of this clinical trial is to assess the safety and efficacy of an investigational vaccine aimed at preventing seasonal flu in adults over 50. An investigational vaccine is a vaccine not yet approved by a country's medicines regulatory agency.

About Seasonal Flu

Seasonal flu is a respiratory illness caused by the flu virus. This virus infects the lungs and breathing passages and is easily spread from person to person.

Every year, seasonal flu causes¹: 3 to 5 million cases of severe illness worldwide

Up to 650,000 deaths worldwide

Seasonal flu more severely affects people 65 years of age and older.¹

The Potential of mRNA Vaccines

Current seasonal flu vaccines are usually only up to 60% effective, and they often perform poorly during years when the circulating flu strains don't match the strains selected for that year's vaccine.² An mRNA vaccine has the potential to offer broader protection by responding to changes in seasonal flu strains more quickly, creating stronger immune responses and improving protection in older adults.³ Right now, research is underway to investigate an mRNA-based flu vaccine to see if it is effective.

Who Can Join?

This clinical trial is looking for adult participants. To join, you must be:

- **50** years of age or older
- Able to follow participation instructions
- Not pregnant or planning on becoming pregnant for at least **3 months following your vaccine visit (as appropriate)**

The clinical trial staff will explain additional trial requirements and can answer any questions you may have.

What Is the Investigational mRNA Vaccine?

This clinical trial is sponsored by Moderna. Moderna is advancing mRNA science to evaluate a new class of investigational vaccines. Moderna is studying the mRNA-1010 investigational vaccine to understand whether it can help your body's immune system protect against seasonal flu.

Vaccines lower your chances of getting a disease by working with your body's natural defences: your immune system. When you get a vaccine, your body's immune system responds and builds protection. Normally, vaccines for viruses are made from a weakened or inactive version of the virus. However, mRNA-1010 is different. The mRNA-1010 investigational vaccine contains mRNA that is entirely made in a laboratory and instructs your body to make small pieces of proteins.

In this case, the investigational vaccine contains the mRNA code for the haemagglutinin (HA) protein of flu. The flu HA protein does not cause seasonal flu infection but may potentially help your body's immune system recognise and protect itself if it comes in contact with the virus. You cannot become infected with seasonal flu from getting the investigational vaccine.



What is the Control?

In order to understand whether the investigational vaccine works, medical researchers are comparing it to an active control, also called an active comparator. An active control is a currently approved vaccine. In this clinical trial, it is a currently approved seasonal flu vaccine made from an inactive flu virus.

Neither you or the clinical trial doctor will know whether you get mRNA-1010 or a currently approved seasonal flu vaccine. Every clinical trial participant will get the same level of high-quality care regardless of whether they are assigned to the investigational vaccine or a currently approved seasonal flu vaccine.

What to Expect

Your participation in the Glow Trial should last about 13 months.

- tossing a coin
- a reason for doing so

Still have guestions? You are encouraged to discuss the risks and benefits of participation with the clinical trial doctor at any time.

Other Considerations

• It will include up to 3 trial visits and up to 6 phone calls to check in about any side effects

 Participants will be given 1 injection in the upper arm. Each participant has a 50% chance of getting the investigational vaccine and a 50% chance of getting a currently approved seasonal flu vaccine – like





 Participants must provide information about their health status and whether they experience any flu

symptoms by entering information into a symptom-reporting electronic diary, or eDiary. Participants will provide information on their health status every day for the first 7 days after receiving the injection. Then for about the first 6 months, participants will report symptoms in the symptom-reporting eDiary twice a week. For the next 6 months, participants will report symptoms once a week

• Enrolling in this clinical trial is completely your choice. You may stop participating in the clinical trial at any time, and you do not have to give

Compensation for your trial-related time may be provided

• If you are planning to get any other vaccine, you must get it at least 28 days before or after getting the clinical trial vaccine

• If you have gotten a seasonal flu vaccine, it must have been at least 6 months before getting the clinical trial vaccine

